Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant IMC-A12 + ADT in High-Risk Prostate Cancer
NCT00769795Phase 2Completed
- Sponsor
- University of Washington
- Start
- Oct 2008
- Primary completion
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in prostate cancer (PCa), sponsored by University of Washington. Started Oct 2008; status: completed.
02
Drugs
cixutumumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00769795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00769795.